Press Release Dec 01 2025
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Wockhardt Limited has submitted a press release regarding the acceptance of its New Drug Application for the antibiotic Zaynich by the US FDA, marking a significant milestone for the company and the Indian pharmaceutical industry. This is the first time an NDA for a New Chemical Entity from an Indian company has been accepted by the US FDA, highlighting Wockhardt's commitment to innovation and scientific excellence. The press release emphasizes Wockhardt's mission to develop advanced anti-infective therapies in response to global healthcare challenges.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Wockhardt
- Press Release Nov 03 2025
- Press Release Oct 01 2025
- Press Release Sep 25 2025
- Press Release Aug 08 2025
- Press Release Jul 28 2025
Later from Wockhardt
- Press Release Dec 31 2025
- Wockhardt Limited Press Release Jan 07 2026
- Wockhardt Limited Press Release Jan 27 2026
- Press Release Feb 10 2026
- Wockhardt Limited Press Release Mar 30 2026
Follow Wockhardt into a list and get an email when it puts out news.
Follow Wockhardt